1. Nambiar and S. C. Raghavan, How does DNA break during chromosomal translocations? NUCLEIC ACIDS RES 39, 5813-5825 (2011).
2. F. F. D'Adda, Living on a break: cellular senescence as a DNA-damage response. NAT REV CANCER 8, 512-522 (2008).
3. P. Jackson and J. Bartek, The DNA-damage response in human biology and disease. NATURE 461, 1071-1078 (2009).
4. Matsuoka, B. A. Ballif, A. Smogorzewska, E. R. McDonald, K. E. Hurov, J. Luo, C. E. Bakalarski, Z. Zhao and N. Solimini, et al., ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. SCIENCE 316, 1160-1166 (2007).
5. T. Paull, Mechanisms of ATM Activation. ANNU REV BIOCHEM 84, 711-738 (2015).
6. Shiloh and Y. Ziv, The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol 14, 197-210 (2013).
7. Squatrito, C. W. Brennan, K. Helmy, J. T. Huse, J. H. Petrini and E. C. Holland, Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. CANCER CELL 18, 619-629 (2010).
8. Ciccia and S. J. Elledge, The DNA damage response: making it safe to play with knives. MOL CELL 40, 179-204 (2010).
9. H. Stracker and J. H. Petrini, The MRE11 complex: starting from the ends. Nat Rev Mol Cell Biol 12, 90-103 (2011).
10. Marechal and L. Zou, DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol 5 (2013).
11. A. Chanoux, B. Yin, K. A. Urtishak, A. Asare, C. H. Bassing and E. J. Brown, ATR and H2AX cooperate in maintaining genome stability under replication stress. J BIOL CHEM 284, 5994-6003 (2009).
12. Shiloh, ATM and related protein kinases: safeguarding genome integrity. NAT REV CANCER 3, 155-168 (2003).
13. Benada and L. Macurek, Targeting the Checkpoint to Kill Cancer Cells. Biomolecules 5, 1912-1937 (2015).
14. N. Teng, N. W. Bateman, K. M. Darcy, C. A. Hamilton, G. L. Maxwell, C. J. Bakkenist and T. P. Conrads, Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells. GYNECOL ONCOL 136, 554-561 (2015).
15. G. Berube, ATRX in chromatin assembly and genome architecture during development and disease. BIOCHEM CELL BIOL 89, 435-444 (2011).
16. J. Law, K. M. Lower, H. P. Voon, J. R. Hughes, D. Garrick, V. Viprakasit, M. Mitson, M. De Gobbi and M. Marra, et al., ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner. CELL 143, 367-378 (2010).
17. P. Voon, J. R. Hughes, C. Rode, I. A. De La Rosa-Velazquez, T. Jenuwein, R. Feil, D. R. Higgs and R. J. Gibbons, ATRX Plays a Key Role in Maintaining Silencing at Interstitial Heterochromatic Loci and Imprinted Genes. CELL REP 11, 405-418 (2015).
18. H. Wong, J. D. McGhie, M. Sim, M. A. Anderson, S. Ahn, R. D. Hannan, A. J. George, K. A. Morgan, J. R. Mann and K. H. Choo, ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells. GENOME RES 20, 351-360 (2010).
19. J. Elsasser, K. M. Noh, N. Diaz, C. D. Allis and L. A. Banaszynski, Histone H3.3 is required for endogenous retroviral element silencing in embryonic stem cells. NATURE 522, 240-244 (2015).
20. W. Leung, G. Ghosal, W. Wang, X. Shen, J. Wang, L. Li and J. Chen, Alpha thalassemia/mental retardation syndrome X-linked gene product ATRX is required for proper replication restart and cellular resistance to replication stress. J BIOL CHEM 288, 6342-6350 (2013).
21. Clynes, C. Jelinska, B. Xella, H. Ayyub, C. Scott, M. Mitson, S. Taylor, D. R. Higgs and R. J. Gibbons, Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX. NAT COMMUN 6, 7538 (2015).
22. Ramamoorthy and S. Smith, Loss of ATRX Suppresses Resolution of Telomere Cohesion to Control Recombination in ALT Cancer Cells. CANCER CELL 28, 357-369 (2015).
23. A. Watson, L. A. Solomon, J. R. Li, Y. Jiang, M. Edwards, K. Shin-ya, F. Beier and N. G. Berube, Atrx deficiency induces telomere dysfunction, endocrine defects, and reduced life span. J CLIN INVEST 123, 2049-2063 (2013).
24. Kovatcheva, W. Liao, M. E. Klein, N. Robine, H. Geiger, A. M. Crago, M. A. Dickson, W. D. Tap, S. Singer and A. Koff, ATRX is a regulator of therapy induced senescence in human cells. NAT COMMUN 8, 386 (2017).
25. Han, J. Cai, W. Gao, X. Meng, F. Gao, P. Wu, C. Duan, R. Wang and M. Dinislam, et al., Loss of ATRX suppresses ATM dependent DNA damage repair by modulating H3K9me3 to enhance temozolomide sensitivity in glioma. CANCER LETT 419, 280-290 (2018).
26. A. Franken, H. M. Rodermond, J. Stap, J. Haveman and C. van Bree, Clonogenic assay of cells in vitro. NAT PROTOC 1, 2315-2319 (2006).
27. Y. Lee, J. A. Han, J. S. Im, A. Morrone, K. Johung, E. C. Goodwin, W. J. Kleijer, D. DiMaio and E. S. Hwang, Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. AGING CELL 5, 187-195 (2006).
28. Singh and S. Roy-Chowdhuri, Quantitative Real-Time PCR: Recent Advances. Methods Mol Biol 1392, 161-176 (2016).
29. van Oorschot, S. Hovingh, A. Dekker, L. J. Stalpers and N. A. Franken, Predicting Radiosensitivity with Gamma-H2AX Foci Assay after Single High-Dose-Rate and Pulsed Dose-Rate Ionizing Irradiation. RADIAT RES 185, 190-198 (2016).
30. Koschmann, P. R. Lowenstein and M. G. Castro, ATRX mutations and glioblastoma: Impaired DNA damage repair, alternative lengthening of telomeres, and genetic instability. Mol Cell Oncol 3, e1167158 (2016).
31. B. Prasad, S. B. Prasad, S. S. Yadav, L. K. Pandey, S. Singh, S. Pradhan and G. Narayan, Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property. Sci Rep 7, 12876 (2017).
32. J. Kang and C. T. Yan, Regulation of DNA repair in the absence of classical non-homologous end joining. DNA Repair (Amst) 68, 34-40 (2018).
33. Enoch and C. Norbury, Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM. TRENDS BIOCHEM SCI 20, 426-430 (1995).
34. Mladenov, S. Magin, A. Soni and G. Iliakis, DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. FRONT ONCOL 3, 113 (2013).
35. M. Heaphy, R. F. de Wilde, Y. Jiao, A. P. Klein, B. H. Edil, C. Shi, C. Bettegowda, F. J. Rodriguez and C. G. Eberhart, et al., Altered telomeres in tumors with ATRX and DAXX mutations. SCIENCE 333, 425 (2011).
36. N. Nguyen, C. M. Heaphy, R. F. de Wilde, B. A. Orr, Y. Odia, C. G. Eberhart, A. K. Meeker and F. J. Rodriguez, Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas. BRAIN PATHOL 23, 237-243 (2013).
37. Ritchie, C. Seah, J. Moulin, C. Isaac, F. Dick and N. G. Berube, Loss of ATRX leads to chromosome cohesion and congression defects. J CELL BIOL 180, 315-324 (2008).
38. J. Brown and D. Baltimore, Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. Genes Dev 17, 615-628 (2003).
39. A. Lovejoy, W. Li, S. Reisenweber, S. Thongthip, J. Bruno, T. de Lange, De S, J. H. Petrini and P. A. Sung, et al., Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLOS GENET 8, e1002772 (2012).
40. Wang, V. C. Lui, R. T. Poon, P. Lu and R. Y. Poon, DNA damage mediated s and g(2) checkpoints in human embryonal carcinoma cells. STEM CELLS 27, 568-576 (2009).
41. Sharma, K. Singh and A. Almasan, Histone H2AX phosphorylation: a marker for DNA damage. Methods Mol Biol 920, 613-626 (2012).
42. Bucher and C. D. Britten, G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 98, 523-528 (2008).
43. C. Acosta and J. Gil, Senescence: a new weapon for cancer therapy. TRENDS CELL BIOL 22, 211-219 (2012).
44. Di X, A. T. Bright, R. Bellott, E. Gaskins, J. Robert, S. Holt, D. Gewirtz and L. Elmore, A chemotherapy-associated senescence bystander effect in breast cancer cells. CANCER BIOL THER 7, 864-872 (2008).
45. Ewald, J. Desotelle, N. Almassi and D. Jarrard, Drug-induced senescence bystander proliferation in prostate cancer cells in vitro and in vivo. Br J Cancer 98, 1244-1249 (2008).
46. Campisi, Cellular senescence: putting the paradoxes in perspective. CURR OPIN GENET DEV 21, 107-112 (2011).
47. P. Coppe, C. K. Patil, F. Rodier, Y. Sun, D. P. Munoz, J. Goldstein, P. S. Nelson, P. Y. Desprez and J. Campisi, Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLOS BIOL 6, 2853-2868 (2008).
48. Kovatcheva, W. Liao, M. E. Klein, N. Robine, H. Geiger, A. M. Crago, M. A. Dickson, W. D. Tap, S. Singer and A. Koff, ATRX is a regulator of therapy induced senescence in human cells. NAT COMMUN 8, 386 (2017).